You are here:

levetiracetam 250 500 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)

Advice

Following a resubmission

levetiracetam (Keppra) is accepted for use within NHS Scotland as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children from 4 years of age with epilepsy.

In the pivotal study, addition of levetiracetam to existing anticonvulsant therapy achieved a greater reduction in partial seizure frequency than addition of placebo.

Drug Details

Drug Name: levetiracetam 250 500 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
SMC Drug ID: 394/07
Manufacturer: UCB Pharma Ltd
Indication: Adjunctive therapy in treatment of partial onset seizures with or without sedondary generalisation in children from 4 years of age with epilepsy
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 11 February 2008

Archived Advice

Full submission 10 September 2007

Back